TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence BARCELONA, ES – Johnson & Johnson (NYSE:JNJ) announced… Read More
Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive BARCELONA, ES – Johnson & Johnson (NYSE:JNJ)… Read More
Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results show potential of RYBREVANT® beyond lung cancer BARCELONA, ES – Johnson & Johnson… Read More
Post-progression outcomes showed significant and sustained improvement for RYBREVANT® plus standard of care versus chemotherapy alone BARCELONA, ES – Johnson & Johnson (NYSE:JNJ) announced updated results from the Phase 3 MARIPOSA-2… Read More
Funding will support the next generation of scientific talent and enhance research excellence Sherbrooke, QC – Canada’s outstanding researchers and institutions are at the forefront of science and innovation, playing… Read More
